Literature DB >> 31808941

Checkpoint inhibitors in AML: are we there yet?

Arnab Ghosh1,2, Pere Barba3, Miguel-Angel Perales1,2.   

Abstract

Immunotherapy is distinct from traditional chemotherapy in that it acts on immune cells rather than cancer cells themselves. Monoclonal antibodies targeting immune checkpoints on T cells - CTLA-4 and PD-1 - and PD-L1 on the cells of immune microenvironment are now approved for clinical use in several solid tumors and hematological malignancies. This article provides a general overview of the use of checkpoint inhibitors in hematologic malignancies with a special focus in acute myeloid leukemia.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  CTLA-4; PD-1; PD-L1; acute myeloid leukemia; checkpoint inhibitors

Mesh：

Substances：

Year:  2019        PMID： 31808941      PMCID： PMC9549702          DOI： 10.1111/bjh.16358

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   8.615


  80 in total

1.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Authors:  Jarushka Naidoo; Xuan Wang; Kaitlin M Woo; Tunc Iyriboz; Darragh Halpenny; Jane Cunningham; Jamie E Chaft; Neil H Segal; Margaret K Callahan; Alexander M Lesokhin; Jonathan Rosenberg; Martin H Voss; Charles M Rudin; Hira Rizvi; Xue Hou; Katherine Rodriguez; Melanie Albano; Ruth-Ann Gordon; Charles Leduc; Natasha Rekhtman; Bianca Harris; Alexander M Menzies; Alexander D Guminski; Matteo S Carlino; Benjamin Y Kong; Jedd D Wolchok; Michael A Postow; Georgina V Long; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

2.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

Authors:  Bing Liao; Sheetal Shroff; Carlos Kamiya-Matsuoka; Sudhakar Tummala
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

Review 3.  Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.

Authors:  Robert R Jenq; Marcel R M van den Brink
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

Review 4.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

Review 5.  Checkpoint Inhibition in Hodgkin Lymphoma - a Review.

Authors:  Paul J Bröckelmann; Andreas Engert
Journal:  Oncol Res Treat       Date:  2017-10-20       Impact factor: 2.825

6.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.

Authors:  Christoph Schmid; Myriam Labopin; Arnon Nagler; Martin Bornhäuser; Jürgen Finke; Athanasios Fassas; Liisa Volin; Günham Gürman; Johan Maertens; Pierre Bordigoni; Ernst Holler; Gerhard Ehninger; Emmanuelle Polge; Norbert-Claude Gorin; Hans-Jochem Kolb; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

7.  Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype.

Authors:  Nargess Arandi; Mani Ramzi; Fatemeh Safaei; Ahmad Monabati
Journal:  Blood Res       Date:  2018-12-17

8.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).

Authors:  Shahram Y Kordasti; Wendy Ingram; Janet Hayden; David Darling; Linda Barber; Behdad Afzali; Giovanna Lombardi; Marcin W Wlodarski; Jaroslaw P Maciejewski; Farzin Farzaneh; Ghulam J Mufti
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

Review 9.  Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

Authors:  Claire F Friedman; Tracy A Proverbs-Singh; Michael A Postow
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962
View more
  9 in total

1.  Clusterization in acute myeloid leukemia based on prognostic alternative splicing signature to reveal the clinical characteristics in the bone marrow microenvironment.

Authors:  Nan Zhang; Ping Zhang; Ying Chen; Shifeng Lou; Hanqing Zeng; Jianchuan Deng
Journal:  Cell Biosci       Date:  2020-10-12       Impact factor: 7.133

2.  eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia.

Authors:  Ziming Jiang; Junyu Long; Kaige Deng; Yongchang Zheng; Miao Chen
Journal:  Front Mol Biosci       Date:  2022-05-02

Review 3.  Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.

Authors:  Pottayil G Sasikumar; Murali Ramachandra
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

4.  Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.

Authors:  Jun Zhang; Lanfen An; Xing Zhou; Rui Shi; Hongbo Wang
Journal:  Ann Transl Med       Date:  2021-04

5.  Checkpoint-blocked T cells checkmate AML.

Authors:  Kirsten M Williams
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

Review 6.  Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.

Authors:  Margaret G Lamb; Hemalatha G Rangarajan; Brian P Tullius; Dean A Lee
Journal:  Stem Cell Res Ther       Date:  2021-03-25       Impact factor: 6.832

Review 7.  Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Kah Keng Wong; Rosline Hassan; Nik Soriani Yaacob
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

8.  The Role of Gender-Related Immune Genes in Childhood Acute Myeloid Leukemia.

Authors:  Lu Hao; Qiuyan Chen; Xi Chen; Qing Zhou
Journal:  Biomed Res Int       Date:  2022-09-23       Impact factor: 3.246

Review 9.  The Role of T Cell Immunotherapy in Acute Myeloid Leukemia.

Authors:  Fang Hao; Christine Sholy; Chen Wang; Min Cao; Xunlei Kang
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.